United States Ophthalmic Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

The United States ophthalmic devices market size is valued at USD 16.65 billion in 2025 and is forecast to reach USD 22.7 billion by 2030, advancing at a 6.48% CAGR over the period.

Rising cataract volumes among adults over 65 years, broader insurance coverage, and continuous upgrades in imaging software collectively underpin this steady expansion. Surgical devices currently command 42.1% of revenue because they enable high-margin refractive, cataract, and glaucoma procedures that few hospitals can defer. Ambulatory surgical centers are the fastest-growing end-user channel, registering a 5.23% CAGR as payers and patients migrate from inpatient to outpatient settings that deliver comparable outcomes at lower cost. Meanwhile, the premium intraocular-lens boom and the rapid adoption of autonomous AI screening tools are reshaping purchasing criteria, prompting device makers to bundle hardware, analytics, and cloud connectivity for lifecycle differentiation.

United States Ophthalmic Devices Market Trends and Insights

Demographic Shift: Myopia & Diabetic Eye-Disease Surge Driving Diagnostic Demand

An aging and increasingly myopic population is materially lifting diagnostic volumes across the United States ophthalmic devices market. Projections indicate that one in two Americans will be myopic by 2050, encouraging payers to consider classifying high myopia as a chronic disease. The diabetic-retinopathy population doubled between 2004 and 2024 to 9.6 million, yet sight-threatening events declined because earlier screening now redirects patients to treatment sooner. Autonomous fundus-photography algorithms installed in community clinics are central to this progress, reducing referral delays and widening access in rural counties.

Rapid Uptake of Premium Cataract & Refractive IOLs Transforming Surgical Outcomes

Surgeons have embraced presbyopia-correcting and extended-depth-of-focus lenses to meet patient demand for spectacle independence. The 2022 ESCRS survey showed a 4% rise in presbyopia-correcting IOL use since 2016, while bifocal models fell to 2% as newer optics improved contrast sensitivity. Johnson & Johnson's TECNIS Odyssey lens, launched in September 2024, already treats more than 14,000 eyes, delivering double the low-light contrast versus earlier multifocal implants. This accelerated turnover drives the United States ophthalmic devices market because surgeons often pair premium lenses with upgraded phaco consoles calibrated for precise lens positioning.

High Capital Outlay for Advanced Diagnostic Suites Limiting Adoption

A full diagnostic bay comprising OCT, corneal topography, and automated refraction can cost more than USD 500,000, straining budgets at independent practices that lack large ASC volumes. With many states seeing flat professional-service fees, these providers hesitate to commit capital that may depreciate in under seven years. Leasing and pay-per-use models mitigate risk, yet present back-office complexity because fees fluctuate with patient load. Consequently, growth in the United States ophthalmic devices market is uneven, with small offices deferring purchases until AI software updates justify their return on investment.

Other drivers and restraints analyzed in the detailed report include:

1. Growth of AI-based OCT & Fundus Imaging Platforms Revolutionizing Diagnostics
2. Expansion of Minimally-Invasive Glaucoma Surgery (MIGS) Implants Driving Surgical Innovation
3. FDA Stringency on Femtosecond & Excimer Laser Upgrades Slowing Innovation Cycles

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Surgical systems generated 42.11% of revenue in 2024 and remain the anchor of the United States ophthalmic devices market because they combine high upfront prices and recurring consumables. The strong performance benefits from sustained premium-IOL penetration, which boosts per-procedure value and nudges surgeons to purchase consoles optimized for toric alignment and astigmatic correction. Networks of ambulatory surgical centers also favor modular femtosecond platforms that fit compact operating rooms. This steady replacement cycle lifts the surgical slice of United States ophthalmic devices market size whenever surgeons retire aging phaco units to support combined MIGS-and-cataract workflows.

Conversely, vision-care devices still dominate unit volumes, accounting for 63.21% of shipments in 2024, yet price erosion and online spectacles discounting limit their value contribution. Contact-lens makers respond with silicone-hydrogel materials that extend oxygen permeability, extending wear times and lowering dropout rates. As users reorder lenses quarterly, suppliers secure predictable cash flow that finances incremental research. The virtuous feedback loop sustains category leadership without materially altering the overall profit mix of the United States ophthalmic devices market.

The United States Ophthalmic Devices Market Report is Segmented by Device Type (Diagnostic & Monitoring Devices, Surgical Devices, and Vision Care Devices), Disease Indication (Cataract, Glaucoma, Diabetic Retinopathy, Other Disease Indications), End-User (Hospitals, Specialty Ophthalmic Clinics, and More. The Market Forecasts are Provided in Terms of Value (USD).

List of Companies Covered in this Report:

1. Alcon
2. Johnson & Johnson
3. Bausch + Lomb Corp.
4. Carl Zeiss
5. EssilorLuxottica
6. Hoya Corp.
7. CooperVision Inc.
8. Glaukos Corp.
9. Topcon Corp.
10. Nidek
11. Ziemer Group
12. Heidelberg Engineering
13. Lumenis
14. Lensar Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support